Phase II trial

Scan to diagnose head and neck cancer
#Cancer vaccine #Head and neck cancer #Oncology #Phase II trial #Scancell Holdings

Vaccine achieves early clinical validation in head and neck cancer

The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study.  The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More

#Cancer Research #News

Human heart
#Cardiovascular disease #Gene therapy #Phase II trial #XyloCor Therapeutics

XyloCor financing advances one-time cardiovascular gene therapy

XyloCor Therapeutics has completed a $67.5 million Series B financing to support a Phase IIb clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec) in refractory angina.  The trial will use a new non‑surgical method of endocardial administration via a novel injection catheter.   The financing will also fund a Phase II trial… Read More

#Business & Investment #News

Optic nerve
#Icahn School of Medicine #Oculis Holding #Ophthalmology #Phase II trial

“Groundbreaking” results in acute optic neuritis trial

A novel peptidomimetic small molecule candidate has met the primary endpoint in a Phase II trial in patients with acute optic neuritis.  Oculis Holding’s neuroprotective candidate OCS-05 also achieved statistical significance on several key efficacy-based secondary endpoints.  The Phase II Acute OptiC NeUrITis of DemYelinating… Read More

#Editor's Choice #News

Degeneration of dopaminergic neuron in Parkinson's disease
#BioArctic #Monoclonal antibodies #Neuroscience #Parkinson's #Phase II trial

Clinical trial will test monoclonal antibody in Parkinson’s disease

BioArctic says it has dosed the first patient with exidavnemab in the EXIST Phase IIa study in Parkinson’s disease patients.   Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders… Read More

#News

Person using a calculator
#Autoimmune disease #Financing #Immunomodulators #Nuvig Therapeutics #Phase II trial

Immunomodulatory therapeutics company raises $161m

Nuvig Therapeutics has closed a $161 million Series B financing and announced plans to progress to Phase II development with its immunomodulator for inflammatory autoimmune diseases.  The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners.  There was also participation from… Read More

#Business & Investment #News

Patient receiving eye drops
#Antibiotic resistance #Antibiotics #Eye health #NTC #Phase II trial

Antibiotic/NSAID combo shows potential for bacterial conjunctivitis

NTC has shared positive results from the Phase II MIRAKLE study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults.  The results show the non-inferiority of NTC014 eye drops vs. antibiotic alone in… Read More

#News

#Clinical trials #Phase I trial #Phase II trial

New DDW Highlights episode: 2 December 2024

The latest episode of the DDW Highlights podcast is now available. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease,… Read More

#News

#Clinical trials #Phase I trial #Phase II trial

This week in drug discovery (25-29 November) 

News round-up for 25-29 November by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease, a new type of drug for type 2 diabetes, a gene therapy for Duchenne muscular dystrophy, a… Read More

#News

Woman reaches for inhaler
#Asthma #AstraZeneca #King's College London #Phase II trial

First new treatment for asthma attacks in 50 years

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%, according to a UK study.  The findings, published in The Lancet Respiratory Medicine, could… Read More

#News #Trending News

Human heart
#Cardiovascular disease #Heart disease #Phase II trial #RNA #Silence Therapeutics

Silence Therapeutics presents late-breaking Phase II data at AHA

Biotechnology company Silence Therapeutics has shared end-of-treatment data from its Phase II ALPACAR-360 study of short interfering RNA (siRNA) zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein levels. These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific… Read More

#News

Lungs
#Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Insilico Medicine #Lung disease #Phase II trial

Positive Phase II results for AI-created pulmonary fibrosis drug

Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055. The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF. The topline results demonstrate that ISM001-055 is… Read More

#News

Tau proteins
#Alzheimer's #Neuroscience #Phase II trial #Tau protein #UCB

Encouraging results for anti-tau antibody presented at CTAD 2024

UCB has reported encouraging Phase IIa data from the TOGETHER (AH0003) study, investigating bepranemab, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease. The results were presented during a late-breaking symposium at the 2024 Clinical Trials… Read More

#News

Peptide
#Cybrexa Therapeutics #Oncology #Ovarian cancer #Peptide-drug conjugate #Peptides #Phase II trial

Peptide-drug conjugate demonstrates antitumour activity

Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer. The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents. Read More

#News

Respiratory system
#Artificial intelligence (AI) #Generative AI #Idiopathic pulmonary fibrosis #Insilico Medicine #Phase II trial

Positive Phase IIa results support AI-powered drug discovery

Insilico Medicine has shared positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). The drug was designed utilising generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary… Read More

#Editor's Choice #News

X-ray showing colon cancer
#Colorectal cancer #Janssen #Monoclonal antibodies #Oncology #Phase II trial

Metastatic colon cancer: 49% response for combination therapy

Janssen-Cilag has shared new data from the Phase Ib/II OrigAMI-1 study at the European Society of Medical Oncology (ESMO) 2024 Congress. The results show that amivantamab combined with chemotherapy demonstrated promising antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not… Read More

#Cancer Research #News #Trending News

#Clinical trial #Clinical trials #GLP-1 #Phase I trial #Phase II trial

New DDW Highlights podcast: 10 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the release of clinical study results that led some media titles to ask… Read More

#News